MedTrace Logo

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

NCT02268929 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 414

Last updated 2017-11-24

No results posted yet for this study

Summary

This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Accu-Chek Smart Pix Software

Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

DEVICE

Accu-Chek Smart Pix readout Device

Smartpix device for data upload out from blood glucose meter devices

Sponsors & Collaborators

Principal Investigators

  • Iris Vesper · Roche Diabetes Care

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-14
Primary Completion
2017-01-11
Completion
2017-02-09

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268929 on ClinicalTrials.gov